Ombitasvir
CAS: 1258226-87-7
Ref. 3D-AO178040
| 25mg | 136.00 € | ||
| 50mg | 180.00 € | ||
| 100mg | 260.00 € | ||
| 250mg | 406.00 € | ||
| 500mg | 542.00 € |
Product Information
- 2,2′-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-<span class="text-smallcaps">L</smallcap>-valyl-<smallcap>L</span>-prolinamide]
- <span class="text-smallcaps">L</smallcap>-Prolinamide, 2,2′-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-<smallcap>L</span>-valyl-
- L-Prolinamide, 2,2′-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-
- ABT 267
- 2,2′-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-L-prolinamide]
Ombitasvir is a potent inducer of the cytochrome P450 enzyme system. It has been shown to inhibit the growth of infectious diseases by binding to α7 nicotinic acetylcholine receptors, which are located on cells in the liver, brain, and other organs. Ombitasvir has also been shown to be a potent inhibitor of antiviral resistance by binding to the viral envelope protein. This drug is used as an oral treatment for chronic hepatitis C infections with or without HIV co-infection in adults. It is also used in combination with other antiviral drugs for the treatment of chronic HBV infection in adults.
Chemical properties
Technical inquiry about: 3D-AO178040 Ombitasvir
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
